Catabasis Pharmaceuticals to Present at International Ataxia Research Conference. CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Andrew Nichols, Ph.D., vice president, head of research at Catabasis, will present a poster titled “CAT-4001, a Novel Nrf2 Activator and NF-kB Inhibitor, for the Treatment of Friedreich’s Ataxia.” The poster will be presented on Friday, March 27, 2015, from 12:00pm to 2:00pm GMT.
Tuesday, March 24, 2015
Subscribe to:
Posts (Atom)
